1
|
Li ZP, Shi YF, Hou LH, Jin PF, Ma SH, Pan HX, Zhang JL, Shan YM, Huang HT, Wu SP, Du P, Wang X, Wang LL, Wang RJ, Wang Y, Wang XW, Zhu FC, Li JX. Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above. Expert Rev Vaccines 2022; 21:1843-1849. [PMID: 36048417 DOI: 10.1080/14760584.2022.2119133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND The demonstration of batch-to-batch consistency is indispensable for quality control of vaccines. METHODS We conducted a randomized, double-blind, parallel-controlled trial to evaluate the immunogenicity consistency of a single shot of Ad5-nCoV in healthy adults who had not previously received any COVID-19 vaccine. All eligible participants were randomly assigned equally to receive one of the three consecutive batches of Ad5-nCoV (5 × 1010 viral particles/vial, 0.5 mL). The primary endpoint was geometric mean titers (GMTs) of serum SARS-CoV-2 receptor-binding domain (RBD)-specific IgG on day 28 post-vaccination. RESULTS One thousand fifty participants were enrolled, with 350 (33%) participants per group. On day 28 post-vaccination, GMTs in three groups were 78.3 binding antibody units (BAU)/mL (95% CI 70.3-87.3), 82.9 BAU/mL (73.9-92.9), and 78.8 BAU/mL (70.2-88.4), respectively. The two-sided 95% CIs for the GMT ratios between each pair of batches were all between 0.67 and 1.5. The highest incidence of solicited adverse reactions within 7 days post-vaccination was reported by batch 3 recipients (23.1% versus 15.1% in batch 1 recipients and 14.6% in bath 2 recipients; p = 0.0039). None of the serious adverse events were related to vaccination. CONCLUSIONS Immunogenicity consistency between consecutive batches of Ad5-nCoV was well established in adults. CLINICAL TRIAL REGISTRATION This trial was registered with ClinicalTrials.gov (NCT05313646).
Collapse
Affiliation(s)
- Zhuo-Pei Li
- School of Public Health, Nanjing Medical University, Nanjing, P.R. China
| | - Yun-Feng Shi
- NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, P.R. China
| | - Li-Hua Hou
- Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P.R. China
| | - Peng-Fei Jin
- NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, P.R. China
| | - Shi-Hua Ma
- Guanyun County Center for Disease Control and Prevention, Guanyun, P.R. China
| | - Hong-Xing Pan
- NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, P.R. China
| | - Jin-Long Zhang
- Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P.R. China
| | - Yong-Mei Shan
- Guanyun County Center for Disease Control and Prevention, Guanyun, P.R. China
| | | | - Shi-Po Wu
- Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P.R. China
| | - Pan Du
- Vazyme Biotech Co. Ltd, Nanjing, P.R. China.,Basic Medical Science School, Zhengzhou University, Zhengzhou, P.R. China
| | - Xue Wang
- CanSino Biologics Inc, Tianjin, P.R. China
| | - Li-Li Wang
- Guanyun County Center for Disease Control and Prevention, Guanyun, P.R. China
| | | | - Ying Wang
- CanSino Biologics Inc, Tianjin, P.R. China
| | - Xue-Wen Wang
- Shanghai Canming Medical Technology Co Ltd, Shanghai, P.R. China
| | - Feng-Cai Zhu
- School of Public Health, Nanjing Medical University, Nanjing, P.R. China.,NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, P.R. China.,Institute of Global Public Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, P.R. China
| | - Jing-Xin Li
- School of Public Health, Nanjing Medical University, Nanjing, P.R. China.,NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, P.R. China.,Institute of Global Public Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, P.R. China
| |
Collapse
|